FDA approves Vibativ for the treatment of bacterial pneumonia caused by Staphylococcus aureus

The U.S. Food and Drug Administration today expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused More...